IKOREL

This brand name is authorized in Australia, France, Ireland, Netherlands, New Zealand, Turkey, UK.

Active ingredients

The drug IKOREL contains one active pharmaceutical ingredient (API):

1	Nicorandil UNII 260456HAM0 - NICORANDIL
	Nicorandil is a derivative of the niacinamide that is structurally combined with an organic nitrate. It provides a dual mode of action leading to relaxation of vascular smooth muscle. Nicorandil is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase. Nicorandil has a direct effect on coronary arteries without leading to a steal phenomenon. The overall action improves blood flow to post-stenotic regions and the oxygen balance in the myocardium.
	Read more about Nicorandil

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
IKOREL Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C01DX16	Nicorandil	C Cardiovascular system → C01 Cardiac therapy → C01D Vasodilators used in cardiac diseases → C01DX Other vasodilators used in cardiac diseases
Discover more medicines within C01DX16

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8228C, 8229D
FR	Base de données publique des médicaments	61613167, 61786176
GB	Medicines & Healthcare Products Regulatory Agency	13999, 15924
IE	Health Products Regulatory Authority	22704, 22793, 28708, 28709, 28713, 28725
NL	Z-Index G-Standaard, PRK	41424
NZ	Medicines and Medical Devices Safety Authority	6595, 6596
TR	İlaç ve Tıbbi Cihaz Kurumu	8699569010463, 8699569010470, 8699569010487, 8699569010494